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Abstract     Goto-Kakizaki (GK) rat is an animal model for spontaneous-onset, non-obese 
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type 2 diabetes. Despite abundant evidence about disorder in metabolism, little information is 
available about fatty acid metabolism in the liver of GK rats. This study aimed to investigate 
the characteristics of the fatty acid profile, particularly MUFA, and the mechanism underlying 
the alterations in fatty acid profile in the liver of GK rats. The activities of enzymes that 
participate in the biosynthesis of MUFA, expressions of genes encoding these enzymes, and 
fatty acid profile in the liver were compared with those of obese Zucker (fa/fa) (ZF) rats, 
which are obese and non-diabetic. Stearoyl-CoA desaturase (SCD) activity and SCD1 gene 
expression were considerably up-regulated in GK rats, and these levels were largely 
comparable to those in ZF rats. However, the proportions and contents of oleic acid and 
palmitoleic acid were very low considering the highly elevated activity of SCD in the liver of 
GK rats, when compared with ZF rats. Palmitoyl-CoA chain elongation (PCE) activity and 
fatty acid elongase (Elovl)6 gene expression were markedly up-regulated in ZF rats, whereas 
PCE activity was up-regulated much less and Elovl6 gene expression was unchanged in GK 
rats. These results suggest the possibility that up-regulation of gene expression of Elovl6 
along with SCD1 is indispensable to elevate the proportions and contents of oleic acid in the 
liver. 
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Elovl       Fatty acid elongase 
ER         Endoplasmic reticulum 
Fads        Fatty acid desaturase 
GK         Goto-Kakizaki 
NADH      Nicotinamide adenine dinucleotide reduced 
NADPH     Nicotinamide adenine dinucleotide phosphate reduced 
PCE        Palmitoyl-CoA chain elongation 
POCE       Palmitoleoyl-CoA chain elongation 
SCD        Stearoyl-CoA desaturase 
SHR        Spontaneously hypertensive 
SHR/NDcp   SHR/NDmcr-cp (cp/cp) 
SREBP-1c   Sterol regulatory element binding protein-1c 
STZ         Streptozotocin-induced diabetic 
VLDL       Very low-density lipoprotein 
WI          Wistar rats, a control corresponding to GK rats 
ZF          Obese Zucker (fa/fa) 
ZL          Lean Zucker (?/+) 
 
 
 
 
 
 
 
 
 
 
Introduction 
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 Biosynthesis of oleic acid (18:1n-9) from palmitic acid (16:0) in the liver is sequentially 
catalyzed by fatty acid elongase (Elovl) 6 and stearoyl-CoA desaturase (SCD)1, and 
palmitoleic acid (16:1n-7) is synthesized by SCD1 from 16:0 [1]. In general, SCD1 and 
Elovl6 are coordinately controlled [2-6]. There is increasing evidence that SCD and its 
products, 18:1n-9 and/or 16:1n-7, in the liver are of crucial importance for many 
physiological processes such as triacylglycerol (TAG) synthesis [1,7], endoplasmic reticulum 
(ER) stress [8-10], secretion of very low-density lipoprotein (VLDL) [11,12] and insulin 
sensitivity [13,14]. Metabolic diseases, dietary states and hormonal states are known to affect 
the proportions of monounsaturated fatty acids (MUFA) in hepatic lipids through changes in 
SCD activity [1]. Among the metabolic diseases, diabetes and obesity are of particular interest. 
It is well established that SCD activity is extremely low in the liver of streptozotocin-induced 
type 1 diabetic rats [6,15]. In contrast, SCD activities in the liver of db/db mice, obese Zucker 
(fa/fa) (ZF) rats and spontaneously hypertensive (SHR)/NDmcr-cp (cp/cp) (SHR/NDcp) rats 
have been demonstrated to be markedly higher than those of their respective controls [16-18]. 
Moreover, the proportions of 18:1n-9 and 16:1n-7 in hepatic lipids of these animals are 
considerably higher than those of the respective control animals [17-19]. db/db mice have a 
point mutation of the leptin receptor gene, and develop obesity, insulin resistance, 
hyperglycemia, hyperinsulinemia and hyperlipidemia associated with type 2 diabetes [20]. ZF 
rats have a mutated leptin receptor and, as a consequence, are hyperphagic, obese, 
hyperlipidemic and insulin-resistant, but do not develop diabetes [21]. SHR/NDcp rats carry a 
nonsense mutation of the leptin receptor gene; the rats spontaneously display typical 
symptoms of metabolic syndrome such as visceral obesity, hypertension, hyperlipidemia, 
hyperglycemia and hyperinsulinemia, and exhibit type 2 diabetes [22]. 
Goto-Kakizaki (GK) rats have been established from normal Wistar rats by selective 
breeding of animals with signs of impaired glucose tolerance [23]. GK rat is an animal model 
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of spontaneous-onset, non-obese type 2 diabetes, featuring postprandial hyperglycemia, 
impaired glucose tolerance, impaired insulin secretion, progressive reduction of β-cell mass 
and the development of long-term diabetic complications [24,25]. The most important 
characteristic of GK rats with regard to lipid metabolism is that this rat has no mutation in the 
leptin receptor gene and is non-obese. GK rats thus offer a convenient model for the study of 
type 2 diabetes, without the confounding effects of obesity. It is necessary to determine the 
characteristics of fatty acid metabolism in the liver to establish GK rats as a useful model for 
research on non-obese type 2 diabetes, because hepatic fatty acid composition is considered to 
be a determinant of insulin sensitivity that acts independently of cellular energy balance and 
stress [26]. To date, however, abnormality of fatty acid metabolism and fatty acid profile in 
GK rats is poorly characterized, and the underlying molecular mechanism is essentially 
unexplored.  
In this context, the present study aimed (i) to uncover the fatty acid profile of lipids and 
(ii) to reveal the roles of fatty acid desaturases and elongases in the regulation of the 
proportion of fatty acids, in particular MUFA, in the liver of GK rats, in comparison with 
those in ZF rats, which is one of the representative models of obesity without diabetes. In the 
present study, we demonstrated (i) that SCD activity is considerably enhanced in the liver of 
GK rats despite the rats not being obese, (ii) that the SCD activity is high considering the very 
low proportions and contents of MUFA in the liver of GK rats and (iii) that the gene 
expression of Elovl6 and the activity of palmitoyl-CoA chain elongation (PCE) in the liver of 
GK rats are markedly lower than those of ZF rats. The present study showed for the first time 
that up-regulation of the expression of the Elovl6 gene along with SCD1 is indispensable to 
increase the proportion and content of 18:1n-9 in the liver by utilizing rats with a 
spontaneously altered metabolic state. 
 
Materials and Methods 
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 Materials     
 
[2-14C]Malonyl-CoA (55 Ci/mol) was purchased from Moravek Biochemicals (Brea, CA). 
Palmitoleoyl-CoA, palmitoyl-CoA, stearoyl-CoA, malonyl-CoA, streptozotocin and bovine 
serum albumin were purchased from Sigma-Aldrich Japan (Tokyo, Japan). Nonadecanoic acid 
was obtained from Nu-Chek-Prep Inc. (Elysian, MN). Nicotinamide adenine dinucleotide 
reduced (NADH) and nicotinamide adenine dinucleotide phosphate reduced (NADPH) were 
obtained from Oriental Yeast Co. (Tokyo, Japan). All other chemicals used were of analytical 
grade.  
 
Animals 
 
All animal procedures were approved by the Josai University’s Institutional Animal Care 
Committee in accordance with the Guidelines for Proper Conduct of Animal Experiments 
(Science Council of Japan). Five-week-old male lean Zucker (?/+) (ZL) and ZF rats were 
obtained from Charles River Japan (Tokyo, Japan). Animals were fed on a standard diet (CE-2, 
Clea Japan Inc.) (Tokyo, Japan) ad libitum and allowed free access to water. After 
acclimatization for at least 1 week, rats were used as follows. GK, WI, ZF and ZL rats were 
fed on the standard diet for 4 weeks and were then killed at the age of 10 weeks. WI rats aged 
5 weeks were made diabetic by an intravenous injection of streptozotocin at a dose of 50-60 
mg/kg of body weight, as described previously [6,15]. The streptozotocin-induced diabetic 
(STZ) rats were fed on the standard diet, and were killed at the age of 10 weeks. Only those 
animals that showed blood glucose levels of more than 500 mg/100 mL were used. Animals 
were anesthetized with diethyl ether, and blood was withdrawn from the inferior vena cava. 
The liver was rapidly removed, washed with saline and weighed. For determination of mRNA, 
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one part of the liver was frozen in liquid nitrogen and then stored at -80°C. The other part of 
the liver was perfused with ice-cold saline, and was used for preparation of microsomes. 
 
Preparation of Microsomes 
 
Livers were homogenized with 4 volumes of 0.25 M sucrose/1 mM EDTA/10 mM Tris-HCl 
(pH 7.4) in a Potter glass-Teflon homogenizer. The homogenates were centrifuged at 18,000 x 
g for 20 min, and the supernatant was centrifuged under the same conditions. The resulting 
supernatant was centrifuged at 105,000 x g for 60 min. The obtained pellet was then 
resuspended in 0.25 M sucrose/0.1 mM EDTA/10 mM Tris-HCl (pH 7.4) and recentrifuged 
under the same conditions. The resulting pellet was resuspended in a small volume of 0.25 M 
sucrose/0.1 mM EDTA/10 mM Tris-HCl (pH 7.4) and used as the microsome fraction. All 
operations were carried out at 0-4°C. Protein concentrations were determined by the method 
of Lowry et al. [27] using bovine serum albumin as a standard.  
 
Analysis of Fatty Acids 
 
After the addition of a known amount of nonadecanoic acid as an internal standard, total lipid 
was extracted from the liver by the method of Bligh and Dyer [28]. Fatty acid methyl esters of 
hepatic lipids were prepared as described previously [17], and the acyl composition of these 
lipids was determined by gas-liquid chromatography (Shimadzu GC-2014; Kyoto, Japan), 
equipped with a flame-ionization detector, using a fused-silica capillary column (SLB-IL100, 
30 m x 0.32 mm internal diameter, film thickness 0.26 µm, Sigma-Aldrich), as described 
previously [29]. 
 
Enzyme Assays  
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 The activities of SCD in microsomes were determined spectrophotometrically as described 
previously [6,15,17] and the activity is presented as the rate constant (k+) for stearoyl-CoA 
stimulated re-oxidation of NADH-reduced cytochrome b5. PCE and palmitoleoyl-CoA chain 
elongation (POCE) in microsomes were assayed as the activities of conversion of 
palmitoyl-CoA to [14C]stearic acid (18:0) and that of palmitoleoyl-CoA to [14C]cis-vaccenic 
acid (18:1n-7), respectively, by estimating the incorporation of the C2 unit from 
[2-14C]malonyl-CoA, essentially according to a method reported previously [30]. In brief, the 
assay mixture contained 15 nmol palmitoyl-CoA or palmitoleoyl-CoA, 100 nmol 
[2-14C]malonyl-CoA (20 nCi), 1 µmol NADPH, 1 µmol NADH, 0.5 µmol KCN, 200-250 µg 
of microsomal protein and 100 mM Tris-HCl (pH 7.4) in a total volume of 0.5 mL. The 
incubation was performed at 37°C for 4 min under nitrogen. 
 
RNA Isolation and Analysis of Gene Expression  
 
Total RNA was isolated from liver tissues using QIAzol reagent and RNeasy kit (QIAGEN, 
Hilden, Germany). cDNA was synthesized from 500 ng of total RNA with avian 
myeloblastosis virus reverse transcriptase (Takara, Shiga, Japan). Polymerase chain reaction 
(PCR) amplification was carried out using SYBR Premix EX Tag (2x) (Perfect Real Time) 
(Takara). The amplification and detection were performed with Applied Biosystems 7500 real 
time PCR system (Life Technologies Corp., Carlsbad, CA). The thermal cycling program was 
as follows: 10 s denaturation step at 95°C, followed by 50 cycles of 5 s denaturation at 95°C 
and 34 s annealing at 60°C. Melting curve analysis was performed to confirm the real-time 
PCR products. Changes in gene expression were calculated by using the comparative 
threshold cycle (Ct) method. Ct values were first normalized by subtracting the Ct value 
obtained from β-actin (control). The sequences of primers used in this study are listed in Table 
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1. 
 
Statistical Analysis 
 
Homogeneity of variance was established using one-way analysis of variance. When a 
difference was significant (p < 0.05), Scheffé’s multiple range test was used as a post hoc test. 
The statistical significance between two groups was analyzed by Student’s t-test after F-test. 
The results were considered as statistically significant with a value of p < 0.05. 
 
Results 
 
SCD Activities in STZ, GK and ZF Rats 
 
SCD activities in hepatic microsomes of STZ, GK, ZF and their respective control rats were 
estimated (Fig. 1). SCD activity in STZ rats was 21% of that in WI rats, although the 
difference was not statistically significant. In contrast, SCD activities in GK and ZF rats were 
higher (363 and 670%, respectively) than those in their respective controls, WI and ZL rats. 
No significant difference was observed in the activity between WI and ZL. It is noteworthy 
that the activity of SCD in GK rats corresponded to 61% of that in ZF rats. 
 
Profile of MUFA in GK and ZF Rats 
 
To understand the characteristics of MUFA synthesis in the liver of GK rats, the fatty acid 
composition of hepatic lipids was analyzed. Table 2 shows the fatty acid profile (mole %) of 
hepatic lipids of GK rats in comparison with that of ZF rats. There were no significant 
differences in fatty acid profile in hepatic lipids between WI and ZL rats, except for 
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8,11,14-eicosatrienoic acid (20:3n-6). The proportion of 18:1n-7 in the liver of GK rats was 
higher (132%) than those of WI rats, whereas no significant change was observed in the 
proportion of 18:1n-9 between GK and WI rats. The proportion of 16:1n-7 in hepatic lipid of 
GK rats was higher (166%) than that of WI rats, the difference being not statistically 
significant. In the liver of ZF rats, the proportions of 18:1n-9, 16:1n-7 and 18:1n-7 were 
higher (294, 469 and 151%, respectively) than those of ZL rats. Fig. 2 shows the differences 
in content (µmole/g liver) of a particular fatty acid between two groups of rats. The 
differences in mass of 18:1n-9 between ZF and ZL rats and between GK and WI rats were 
30.82 and 1.69 µmol/g liver, respectively. Those of 16:1n-7 between ZF and ZL rats and 
between GK and WI rats were 10.91 and 1.03 µmol/g liver, respectively. Those of 18:1n-7 
between ZF and ZL rats and between GK and WI rats were 5.30 and 1.31 µmol/g liver, 
respectively. Thus, among the MUFA, the extents of the increases in the proportions and 
contents of 18:1n-9 and 16:1n-7 in GK rats were markedly lower than those in ZF rats. On the 
other hand, no considerable difference was observed in the proportion of 18:1n-7 between GK 
and ZF rats. 
 
 Desaturases and Elongases Involved in Biosynthesis of MUFA 
 
The microsomal activities of PCE and POCE in the liver were determined (Fig. 3). The 
activity of PCE in GK rats was higher (136%) than that in WI rats. On the other hand, PCE 
activity in ZF rats was higher (250%) than that of ZL rats (Fig. 3A). The activity of PCE in 
GK rats was 63% of that in ZF rats. No considerable difference was observed in PCE activity 
between WI and ZL rats. No notable difference was observed in POCE activity among GK, 
ZF and WI rats (Fig. 3B). 
The levels of mRNA encoding key enzymes that control MUFA composition of hepatic 
lipids in the liver of GK rats were estimated in comparison with those of ZF rats (Fig. 4). With 
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regard to the expression of genes encoding SCD, the levels of SCD1 mRNA in GK and ZF 
rats were higher (192 and 889%, respectively) than those of their respective controls. The 
level of SCD1 mRNA in ZF rats was higher (169%) than that in GK rats. There was no 
difference in the expression of SCD2 gene among the four groups of rats. As for Elovls, the 
level of Elovl6 mRNA in ZF rats was higher (2930%) than that of ZL rats. The level of Elovl6 
mRNA in GK rats was 5.6% of that in ZF rats. There was no significant difference in the level 
of Elovl6 mRNA between WI and GK rats. The level of Elovl5 mRNA in GK rats was higher 
(158%) than that in WI rats. The level of Elovl5 mRNA in ZF rats was 49% of that in GK rats, 
and no significant difference was observed in the level of Elovl5 mRNA between ZL and ZF 
rats.  
 
Profile of Polyunsaturated Fatty Acid (PUFA) in GK and ZF Rats 
 
There was a marked difference in the composition of PUFA in the liver between ZF and ZL 
rats (Table 2). Proportions of arachidonic acid (20:4n-6) and linoleic acid (18:2n-6) in ZF rats 
were 40 and 61%, respectively, of those in ZL rats, but hepatic content of 18:2n-6 in the liver 
of ZF rats was almost the same as that of ZL rats (23.1 vs. 25.0 µmole/g liver). The proportion 
of 20:3n-6 in ZF rats was higher (179%) than that in ZL rats. On the other hand, no significant 
difference was found in the proportions of 20:4n-6 and 20:3n-6 between GK and WI rats, 
whereas the proportion of 18:2n-6 in GK rats was 80% of that in WI rats. As shown in Fig. 4, 
the mRNA level of fatty acid desaturase (Fads)1 in GK rats was higher (184%) than that in 
WI rats. The level of Fads1 mRNA in ZF rats was 31% of that in ZL rats and was 18% of that 
in GK rats. There was no significant difference in gene expression of Fads2 among WI, GK 
and ZL rats. The mRNA level of Fads2 in ZF rats was 79% of that in ZL rats and was 54% of 
that in GK rats. 
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Discussion 
 
SCD has received considerable attention for its regulation by hormones and nutrients and its 
capacity to generate MUFA. In terms of hormones, insulin strongly regulates SCD in the liver, 
so that this activity is suppressed in animal models of type 1 diabetes such as STZ rats [6,15]. 
In contrast, the activity is reported to be profoundly augmented in the liver of obese animals 
that carry mutated leptin receptor gene such as ZF rats [17,31]. In accordance with these 
previous findings, our current study confirmed that SCD activity in the liver of STZ rats 
showed an obvious tendency to be lower and that the activity in the liver of ZF rats is 
strikingly high. Interestingly, the present study provided evidence that the activity of SCD in 
the liver of GK rats is at an intermediate level in ZF and control rats and is much higher than 
that in STZ rats. The activity in GK rats (estimated as rate constant k+ = 3.2) corresponded to 
61% of that in ZF rats (k+ = 5.2) and is comparable to the SCD activity in SHR/NDcp rats (k+ 
= 3.8). SHR/NDcp rats display markedly enhanced activity of SCD and abnormally high 
proportions of 18:1n-9 and 16:1n-7 in their liver [18]. To the best of our knowledge, this is the 
first evidence showing that the SCD activity in the liver of diabetic and non-obese animals is 
augmented up to a level comparable to that of obese rats. These results prompted us to 
anticipate elevated proportions of MUFA in the liver of GK rats. The analyses of fatty acid 
composition revealed, however, that a notable increase did not occur in the proportions and 
contents of MUFA in hepatic lipids of GK rats, whereas striking elevations of the proportions 
and contents of MUFA, in particular 18:1n-9 and 16:1n-7, were confirmed in hepatic lipids of 
ZF rats. These results strongly indicate that the proportions and contents of 18:1n-9 and 
16:1n-7 are very low considering the high activity of SCD in the liver of GK rats. 
Fatty acids are synthesized de novo from acetyl-CoA, and the liver modifies fatty acid 
structure through a metabolic pathway that includes fatty acid desaturation and chain 
elongation. Such modifications occur to fatty acids generated de novo as well as fatty acids 
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derived from the diet. In contrast to SCD, elongases have only recently been recognized as 
important contributors to the regulation of hepatic lipid composition [5]. To elucidate the 
mechanism underlying the fatty acid profile in the liver of GK rats, we estimated the activities 
of PCE and POCE in hepatic microsomes of GK rats and compared the results with those 
from ZF rats. The activity of PCE in GK rats was slightly higher than that in control rats. On 
the other hand, PCE activity in ZF rats was much higher (250%) than that in corresponding 
control rats. The case of POCE was entirely different from that of PCE. Roughly, there was no 
marked difference in POCE activity among GK, ZF, and their corresponding control rats. 
To gain insights into the molecular basis of regulation of SCD, PCE and POCE, the 
expressions of genes encoding SCD and fatty acid elongases were estimated. For SCD, two 
genes encoding the enzyme have been reported in the liver of rats [32]. Of these subtypes, 
SCD1 is expressed at a high level in the liver of animals with altered pathophysiological 
states, such as ZF and SHR/NDcp rats [1,14,17,18] . The present study demonstrated that the 
gene expression of SCD1 in GK rats was approximately 2 times higher than that in control 
rats. In accordance with previous studies [17], the expression of SCD1 gene in ZF rats was 
profoundly higher than that in ZL rats. Consequently, the level of SCD1 mRNA in the liver of 
ZF rats was higher (889%) than that of ZL rats, and was higher (169%) than that of GK rats. 
On the other hand, there was no significant difference in the expression of the gene encoding 
SCD2 among GK, ZF and their respective control rats. As for Elovls, Elovl6 expression was 
strikingly high in the liver of only ZF rats, whereas the level of Elovl6 expression in GK rats 
was only 5.6% of that in ZF rats. On the other hand, the expression of Elovl5 in GK rats was 
slightly, but significantly, higher than that in control rats and was about 2 times higher than 
that in ZF rats. The translated product of Elovl6 is considered to have a substrate preference 
for 16:0 [5,33]. Elovl5 product preferentially converts 16:1n-7 to 18:1n-7, whereas 16:0 is a 
poor substrate for this protein [5,33]. On the basis of these findings, in a previous study on 
SHR/NDcp rats, we developed the hypothesis that PCE is largely composed of Elovl6 product 
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and that POCE consists of two elongases with a relatively large proportion of Elovl5 product 
and a relatively small proportion of Elovl6 product [18]. This hypothesis may enable us to 
explain the difference in the proportions of MUFA between GK and ZF rats (Fig. 5). Namely, 
in the liver of ZF rats, the activities of SCD and PCE were markedly high, primarily due to 
the enhanced gene expressions of both SCD1 and Elovl6, but the activity of POCE was not 
altered, owing to unchanged expression of the Elovl5 gene, so that the proportions and 
contents of 18:1n-9 and 16:1n-7 were strikingly elevated, but that of 18:1n-7 was increased to 
a lesser extent. On the other hand, in the liver of GK rats, the activity of SCD was 
up-regulated, due to substantial increase in SCD1 expression. As for fatty acid elongase in GK 
rats, however, the activity of PCE was slightly enhanced, with no statistically significant 
difference in Elovl6 expression between GK and control rats; conversely, despite the 
expression of Elovl5 in GK rats being considerably higher than that in control rats, the 
activity of POCE in GK rats was slightly, but not significantly, higher than that in control rats, 
so that the proportions of MUFA were little changed. These results would indicate that 
transcription levels may not be directly related to enzyme activities. It still remains to be 
resolved why the proportion and content of 16:1n-7 were very low considering the high 
activity of SCD in the liver of GK rats. It is worth noting, however, that contents of 16:0, 
which is a substrate for the synthesis of 16:1n-7 or 18:1n-9 via stearic acid (18:0), in the liver 
of GK and ZF rats were 23.87 and 58.46 µmole/g liver, respectively, and the difference in 
mass of 16:0 between ZF and ZL rats and between GK and WI rats were 28.83 and 1.53 
µmole/g liver, respectively. One may suspect, therefore, the possibility that SCD in the liver 
of ZF rats is able to utilize large amounts of 16:0 as substrate; on the other hand, 16:0 is less 
available for SCD in the liver of GK rats, despite the fact that the SCD activities in GK and 
ZF rats are roughly similar. 
With regard to the regulation of SCD and PCE, numerous studies have been reported. 
The activities of SCD and PCE in the liver are considered to be coordinately controlled in 
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response to hormonal, dietary and pharmacological changes [4-6, 15, 29, 30]. The present 
study showed the coordinated up-regulation of these enzymes in ZF rats that are 
spontaneously obese and non-diabetic. Similarly, SCD and PCE are both up-regulated in the 
liver of SHR/NDcp rats that is spontaneously type 2 diabetic and obese [18]. This coordinated 
regulation of SCD and PCE is considered to be mediated by transcription factors, sterol 
regulatory element binding protein-1c (SREBP-1c), carbohydrate responsive element binding 
protein, liver X receptor and peroxisome proliferator activated receptor α, which regulate the 
expressions of SCD1 and Elovl6 [2]. Interestingly, Elovl6 deficiency is associated with the 
down-regulation of SCD1 gene expression [26]; conversely, liver-specific SCD1 knockout is 
associated with the reduced expression of Elovl6 [34]. These findings, taken together, may 
prompt one to conjecture close relationship between SCD1 and Elovl6. It is attractive to 
suspect that the similarity of SCD1 and Elovl6 in ER location, gene structures and 
coordinating functions of both proteins implicates that these genes could be derived from a 
common ancestral gene, a hypothesis that is presented by Matsuzaka and Shimano [35]. In 
this context, therefore, the case of GK rats must be very exceptional and surprising, the 
conclusion which could come from observation that the expressions of SCD1 and Elovl6 were 
not coordinately regulated in the liver of GK rats. It seems that a unique mechanism is 
involved in the regulation of SCD1 and/or Elovl6 in the liver of GK rats. The precise 
molecular mechanism for this, however, is currently unknown. 
The present study clearly showed that ZF rats displayed a considerably low proportion of 
20:4n-6 in the liver, whereas GK rats did not. The conversion of 18:2n-6 to 
6,9,12-octadecenoic acid (18:3n-6) is catalyzed by Δ6 desaturase, which is encoded by Fads2; 
18:3n-6 is then elongated to 20:3n-6 by elongase that is encoded by Elovl5; 20:3n-6 is 
desaturated to 20:4n-6 by Δ5 desaturase, which is encoded by Fads1 [36]. Therefore, changes 
in the activities of Δ6 and Δ5 desaturases are considered to be critical for the generation of the 
PUFAs of n-6 series [37]. The present results showed that hepatic contents of 18:2n-6 in the 
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liver of ZL and ZF rats were almost equal, indicating no difference in the amounts of the 
substrate available for 20:4n-6 synthesis between ZL and ZF rats. On the other hand, the 
present study showed that the level of Fads1 mRNA in ZF rats was strikingly lower than that 
in ZL rats. This strong down-regulation of expression of Fads1 gene seems to result in the 
accumulation of 20:3n-6 and the decreases in the proportion and content of 20:4n-6 in hepatic 
lipids of ZF rats. These results are virtually consistent with the findings reported previously 
[31,38]. Moreover, it should be noted that the present study provided evidence that the levels 
of mRNAs for Fads1, Fads2 and Elovl5 in GK rats were significantly higher than those in ZF 
rats. These results, taken together, well elucidate the fact that the proportion of 20:4n-6 was 
lower and that of 20:3n-6 was higher in the liver of ZF rats and that these fatty acids were at 
normal proportions in the liver of GK rats (Fig. 6). Thus, the metabolism of PUFAs in the 
liver of GK rats is largely normal. 
The present study revealed the higher contents of 18:1n-9 (530%), 16:1n-7 (830%), 
18:1n-7 (270%) and 16:0 (198%) in the liver of ZF rats. The hepatic profile of MUFA and 
saturated fatty acids (SFAs) in ZF rats is very similar to that of SHR/NDcp rats [18], which 
display spontaneous obesity, hypertension, hypertriglyceridemia and type2 diabetes [22]. 
These findings strongly imply that hepatic MUFA play a pathophysiologic role in the process 
of obesity or metabolic syndrome. However, little is known about pathophysiologic 
significance of the changes in hepatic content of MUFA. It has been well studied that ZF rats 
display hepatic and peripheral insulin resistance [39], hepatic steatosis [40], resistance to the 
inhibitory effects of insulin on VLDL production (i.e. hypertriglyceridemia) [41], and TAG 
accumulation in adipose tissues (i.e. obesity) [21]. Nevertheless, to our knowledge, there is 
little evidence to link the findings of up-regulations of MUFA biosynthesis and the findings of 
pathophysiologic processes in ZF rats together. Recently, Buqué et al. has demonstrated that 
genes of fatty acid synthase, SCD1, malic enzyme and fatty acid translocase/CD36 are 
up-regulated in the liver of ZF rats and that the elevated expressions of these four genes 
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significantly correlated with severity of hepatic steatosis, which is responsible for marked 
increase in hepatic content of TAG [42]. These findings strongly suggest increased formation 
of 16:0 and MUFA, although they did not present evidence with regard to the changes in fatty 
acid profile in the liver. An excess of SFAs such as 16:0 is known to cause ER stress [8-10], 
which in turn is causative of hepatic insulin resistance [43]. It is considered that hepatic ER 
stress may generally ensue when the hepatic capacity to degrade fatty acids, store fatty acids 
as TAG, and export TAG as VLDL is overwhelmed by hepatic de novo fatty acid synthesis. In 
insulin-resistant state, VLDL is overproduced as a safeguarding to protect against the further 
development of steatosis, leading to hypertriglyceridemia [44]. As a result, massive fatty acids 
are delivered to adipose tissues where the fatty acids are stored as TAG, which causes obesity. 
Once storage capacity of adipose tissues is exceeded, then net flux of fatty acids from visceral 
adipose tissues to the liver increases; this ectopic lipid accumulation in the liver worsens 
lipotoxic effects [45]. In the vicious cycle that leads to the progression of hepatic steatosis, 
hypertriglyceridemia, obesity and insulin resistance, fatty acid species plays a pivotal role. 
Notably, SFA are more toxic than MUFA in their capacity to induce ER stress [46, 47]. 
Namely, excess 16:0 alone is poorly incorporated into TAG, and co-treatment with 18:1n-9 or 
increased expression of SCD1 can divert 16:0 to TAG formation [48]. Thus, TAG containing 
18:1n-9 may be stored as inert lipid stores with regard to lipotoxicity, so that SFA toxicity can 
be abrogated [46,48]. In this context, Stefan et al. have suggested that high hepatic SCD1 
activity may regulate TAG accumulation in the liver and possibly protects from insulin 
resistance in obese humans [49]. Moreover, Li et al. showed that up-regulation of hepatic 
SCD1 may be a crucial adaptive mechanism in the prevention of liver damage and hepatitis in 
hepatic steatosis in mice [50]. Our present study showed striking increase in contents of both 
16:0 and 18:1n-9, and up-regulations of both PCE (Elovl6) and SCD (SCD1) in the liver of 
ZF rats. Considering the pathophysiologic roles of 18:1n-9 as argued above, it seems likely 
that the elevated formation of 18:1n-9 from 16:0 by the coordinated action of Elovl6 and 
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SCD1 in the liver of ZF rats is to maintain cellular 16:0 at low level enough to prevent ER 
stress and insulin resistance by sequestering fatty acids into inert TAG and by exporting fatty 
acids as VLDL-TAG. Additionally, PUFAs, in particular 20:4n-6, strongly suppress expression 
of SREBP-1c [51], and 18:1n-9 as well as PUFAs is shown to increase Insig-1, a protein that 
retains SREBP-1c in ER membrane, leading to prevention of maturation of SREBP-1c to its 
nuclear form [52]. The present study showed that hepatic content of 20:4n-6 is lower by 30% 
and that of 18:1n-9 is higher (530%) than control rats. It seems likely, therefore, that the 
alteration occurred in fatty acid profile in the liver of ZF rats tends to improve inappropriately 
elevated lipogenesis. Nevertheless, insulin may continue to stimulate SREBP-1c activity and 
lipogenesis in livers of ZF rats that are otherwise insulin resistance. Thus, the combination of 
insulin resistance (inappropriate gluconeogenesis) and insulin sensitivity (elevated 
lipogenesis) may establish a vicious cycle that aggravates hyperinsulinemia and insulin 
resistance in ZF rats. On the other hand, GK rats display hepatic and peripheral insulin 
resistance (type 2 diabetes) [53] and a slight increase in VLDL-TAG [54], without obesity. 
Surprisingly, the present study has shown the up-regulation of SCD1, but not Elovl6, and little 
change in contents of MUFA in the liver of GK rats. The phenomenon that the expression of 
SCD1 is significantly elevated in the liver in GK rats is particularly interesting, but it is yet 
unclear how the up-regulation of SCD1 plays pathophysiologic role in the processes of type 2 
diabetes in GK rats.  
There is growing evidence that 16:1n-7 has notable physiologic benefits. Adipose-tissue 
derived 16:1n-7 was reported to act as a lipokine, improve insulin action and suppress 
hepatosteatosis through down-regulation of hepatic SCD1 and decreased TG synthesis [13]. A 
recent study has shown that 16:1n-7 supplemented with diet to mice improves insulin 
sensitivity, suppresses liver inflammatory response and paradoxically induces hepatic 
steatosis through up-regulation of fatty acid synthase in the liver [55]. Thus, physiologic 
significance of 16:1n-7 as a lipokine has not been fully elucidated. On the other hand, a 
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number of studies indicate that 16:1n-7 is capable of reducing ER stress in many types of cells 
including hepatocytes [56, 57]. More recently, Tripathy and Jump has provided evidence 
strongly suggesting that 18:1n-7 produced from 16:1n-7 by Elovl5 down-regulates 
gluconeogenesis in the liver [58]. Our present study showed that 16:1n-7 content was 
markedly higher (830%) in the liver of ZF rats and that hepatic content of 16:1n-7 in GK rats 
tended to be higher (172%), the difference being not statistically significant. However, further 
studies are required to determine whether 16:1n-7 produced in the liver per se and 18:1n-7 
produced from 16:1n-7 act as a factor to prevent or aggravate metabolic disorder in these rats. 
Many attempts have been made to understand the physiological roles of SCD1, Elovl6 
and Elovl5 by means of genetic engineering of animals or cells. In this regard, however, 
model animals that are spontaneously altered in the regulation of Elovl6 independently of 
SCD1 expression have not been found, so that little has been resolved about whether 
regulation of SCD1 in concert with Elovl6 is required for the formation of 18:1n-9 in vivo in 
the liver. The present study provided evidence that up-regulation of Elovl6 along with SCD1 
is indispensable in the augmented formation of 18:1n-9 in the liver. To our knowledge, this 
study is the first to constitute insight in the relationships between fatty acid desaturation and 
elongation and fatty acid profile in the liver of GK rats. 
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Figure legends 
 
Fig. 1   Activities of SCD in hepatic microsomes of STZ, GK and ZF rats. Values represent 
mean ± SD (n = 4). a, b Differences without a common superscript are statistically significant 
(P < 0.05). 
 
Fig. 2    Differences in content (µmole/g liver) of fatty acids in hepatic lipids between GK 
and WI rats and between ZF and ZL rats. With regard to each fatty acid, differences in content 
between the means of WI and GK rats and between ZL and ZF rats were calculated from the 
data in Table 2. 
 
Fig. 3   Activities of PCE (A) and POCE (B) in hepatic microsomes of GK and ZF rats. 
Values represent mean ± SD (n = 4). a, b Differences without a common superscript are 
statistically significant (P < 0.05).  
 
Fig. 4   Levels of mRNA encoding SCD1, SCD2, Elovl5, Elovl6, Fads1 and Fads2 in the 
liver of GK and ZF rats. Values represent mean ± SD (n = 4). a, b, c Differences without a 
common superscript are statistically significant (P < 0.05). If no superscript appears, the 
differences in the means are not significant (P > 0.05). 
 
Fig. 5    Diagram of enzymes regulating synthesis of 16:1n-7, 18:1n-7 and 18:1n-9. 
 
Fig. 6    Diagram of enzymes regulating synthesis of 20:3n-6 and 20:4n-6 
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Table 1 Sequences of primers used for real-time PCR 
Primer sequence (5' -3') Accession No. 
Elovl5 F : ACCACCATGCCACTATGCTCA AB071985 
R : GGACGTGGATGAAGCTGTTG 
Elovl6 F : AGAACACGTAGCGACTCCGAA AB071986 
R : CAAACGCGTAAGCCCAGAAT 
Fads1 F : TACAGGCAACCTGCAACGTTC NM_053445 
R : GGTGCCACCTTGTGGTAGTTGT 
Fads2 F : GCCACTTAAAGGGTGCCTCC BC081776 
R : TGCAGGCTCTTTATGTCGGG 
SCD1 F : TCACCTTGAGAGAAGAATTAGCA J02585 
R : TTCCCATTCCCTTCACTCTGA 
SCD2 F : TGCACCCCCAGACACTTGTAA AB032243 
R : GGATGCATGGAAACGCCATA 
β-Actin F : TGCAGAAGGAGATTACTGCC V01217 
R : CGCAGCTCAGTAACAGTCC 
1 
Table 2    Fatty acid profile (mole %) of hepatic lipid of GK and ZF rats 
 
Fatty acids WI GK ZL ZF 
16:0 25.47 ± 1.26 26.30 ± 2.09 28.87 ± 5.92 32.07 ± 2.67 
16:1n-7 1.63 ± 0.23a 2.70 ± 0.13a 1.43 ± 0.61a 6.70 ± 1.12b 
18:0 16.70 ± 0.59a 16.25 ± 1.57a 17.52 ± 1.93a 10.96 ± 2.56b 
18:1n-9 7.47 ± 0.52a 8.97 ± 0.68a 7.05 ± 0.87a 20.71 ± 2.19b 
18:1n-7 4.01 ± 0.30ac 5.28 ± 0.20b 3.09 ± 0.34a 4.66 ± 0.92bc 
18:2n-6 21.62 ± 0.74a 17.29 ± 1.67b 23.22 ± 0.68a 14.05 ± 1.68c 
18:3n-3 0.46 ± 0.03 0.42 ± 0.08 0.36 ± 0.05 0.35 ± 0.07 
20:3n-9 0.06 ± 0.03 0.06 ± 0.01 0.11 ± 0.05 0.12 ± 0.11 
20:3n-6 1.24 ± 0.15a 0.97 ± 0.11ac 0.75 ± 0.17bc 1.34 ± 0.30a 
20:4n-6 14.47 ± 0.72a 15.61 ± 1.02a 12.87 ± 2.84a 5.11 ± 1.24b 
20:5n-3 1.13 ± 0.10 0.97 ± 0.12 0.96 ± 0.33 0.81 ± 0.18 
22:5n-3 1.62 ± 0.15a 1.46 ± 0.27ac 1.13 ± 0.53ac 0.83 ± 0.18bc 
22:6n-3 4.14 ± 0.15a 3.75 ± 0.32ac 2.68 ± 1.25ac 2.30 ± 0.77bc 
Total (μmol/g liver) 87.58 ± 4.58a 91.27 ± 10.84a 99.82 ± 18.07a 179.78 ± 44.97b 
Values represent mean ± SD (n=4). Differences in horizontal means without a common 
superscript (a, b, c) are significant ( p＜0.05 ). If no superscript appears, the differences in the 
means are not significant ( P＞0.05 ). 
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